Anantha Marisetty Ph.D.’s Post

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> #JPM24: Merck is eyeing new immunology deals, chief medical officer says: Merck wants to beef up its immunology pipeline through additional deals, the Big Pharma’s chief medical officer Eliav Barr said at an Endpoints News event on Tuesday. “We’ll be looking for those immunology opportunities that we think can complement or add a new facet to things,” Barr said. The big pharma, which houses the best-selling cancer medicine Keytruda, has invested substantially in immunology in recent years, including a $10.8 billion buyout of Prometheus last year. That deal gave Merck an experimental treatment for inflammatory bowel diseases and firmly moved the company into the immunology field. “Something that’s underappreciated about the deal was all that was behind it,” Barr said. “It was the biomarker selection strategy, access to this extraordinary annotated database that was really useful, and a lot of early clinical and preclinical candidates.” Merck has emphasized expanding outside of oncology and Keytruda, focusing in particular on cardiometabolic drugs and immunology. “Just because we’re really strong in oncology doesn’t give us carte blanche to say we’re always going to be successful in oncology,” Barr said. “If you see the diversification of what we’ve done — and for me that means, whatever the sciences is, is where we’re going to go — if it means building a new immunology franchise, that’s what we’re going to do.” When asked about Merck’s former head of R&D Roger Perlmutter’s comment to Endpoints that the pharma company had fallen into “franchise thinking,” Barr said that “the ‘we’ve always done it this way’ approach is the killer approach — that kills science. You need to be objective; you need to check your own BS. “Don’t fall in love with yourself so much. We’re always skeptical about everything that we do,” he said. #lucidquest #genetherapy #celltherapy

Here’s a brilliant example of using #hiring with keywords: 👀 a hiring manager posting for a role on their team. Big picture summary and link to the job on the company website. Important notes: 1. You know who to address your cover letter to! 2. You can ask the HM questions about the role to learn more 3. You might not find this on the LinkedIn job board. #postdoc #phd #jobsearch

📃Scientific paper: Multi-objective optimization based network control principles for identifying personalized drug targets with cancer Abstract: It is a big challenge to develop efficient models for identifying personalized drug targets (PDTs) from high-dimensional personalized genomic profile of individual patients. Recent structural network control principles have introduced a new approach to discover PDTs by selecting an optimal set of driver genes in personalized gene interaction network (PGIN). However, most of current methods only focus on controlling the system through a minimum driver-node set and ignore the existence of multiple candidate driver-node sets for therapeutic drug target identification in PGIN. Therefore, this paper proposed multi-objective optimization-based structural network control principles (MONCP) by considering minimum driver nodes and maximum prior-known drug-target information. To solve MONCP, a discrete multi-objective optimization problem is formulated with many constrained variables, and a novel evolutionary optimization model called LSCV-MCEA was developed by adapting a multi-tasking framework and a rankings-based fitness function method. With genomics data of patients with breast or lung cancer from The Cancer Genome Atlas database, the effectiveness of LSCV-MCEA was validated. The experimental results indicated that compared with other advanced methods, LSCV-MCEA can more effectively identify PDTs with the highest Area Under the Curve score for predicting clinically annotated combinatorial drugs. Meanwhile, LSCV-MCEA can more effectively solve MONCP than other evolutionary... Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/MbHJ

Techbio Unicorn Owkin Unveils AI-Driven Oncology and Immunology Pipeline : 4 early-stage de novo drug discovery programs and 1 patent-protected in-licensed drug asset ! 🤖𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 Owkin's pipeline leverages several internal AI engines and multimodal patient data from 61 research centers. With a team of 110 data scientists, Owkin uses spatial multiomics data via MOSAIC, the world's largest dataset in oncology, to understand the tumor microenvironment. This expertise positions Owkin to tackle challenges in precision medicine. 🧬𝐀𝐈 𝐄𝐧𝐠𝐢𝐧𝐞𝐬 𝐒𝐞𝐥𝐞𝐜𝐭 𝐎𝐊𝐍𝟒𝟑𝟗𝟓 𝐟𝐨𝐫 𝐢𝐧𝐥𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 Owkin's biomarker engine created detailed EP2/EP4 signatures using multimodal patient data, identifying actionable biomarkers. The AI drug positioning engine screened over 30 cancer indications for OKN4395, identifying the most promising therapeutic combinations for clinical trial 👩⚕️𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐎𝐊𝐍𝟒𝟑𝟗𝟓 Owkin plans to use its clinical trial optimization solutions to bring OKN4395 to the patients most likely to benefit from this innovative therapeutic. By utilizing its unique AI-driven pipeline, Owkin aims to enhance precision medicine in oncology and immunology.success.

🧬🔬 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐆𝐞𝐧𝐨𝐦𝐞 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐔𝐧𝐫𝐚𝐯𝐞𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐟𝐨𝐫 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 🌐💊 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gbyNgV2c 🔍 Key Highlights: Genomic Profiling: Cancer genome sequencing enables comprehensive profiling of tumor genomes, transcriptomes, and epigenomes, providing insights into the molecular alterations, genetic mutations, and signaling pathways driving tumorigenesis, disease progression, and treatment resistance in diverse cancer types. Next-generation sequencing (NGS) technologies, whole-genome sequencing (WGS), whole-exome sequencing (WES), and targeted sequencing panels facilitate high-throughput analysis of tumor samples, identifying somatic mutations, copy number variations (CNVs), chromosomal rearrangements, and driver mutations that inform oncogenic mechanisms, therapeutic vulnerabilities, and prognostic markers in cancer patients. Precision Oncology: The Cancer Genome Sequencing Market is advancing the paradigm of precision oncology, tailoring cancer treatments to the molecular characteristics, genomic signatures, and therapeutic targets identified through tumor sequencing and molecular profiling. Molecularly guided treatment strategies, targeted therapies, and immunotherapies offer personalized treatment options that match patients with the most effective drugs, biomarker-driven clinical trials, and combination regimens based on the genetic profile of their tumors, optimizing treatment responses, prolonging survival, and improving clinical outcomes in cancer patients. Liquid Biopsies: Liquid biopsy assays, circulating tumor DNA (ctDNA) analysis, and non-invasive genomic testing methods are transforming cancer diagnosis, monitoring, and treatment response assessment, offering minimally invasive alternatives to traditional tissue biopsies for detecting tumor-derived DNA fragments, monitoring disease dynamics, and tracking treatment response in real time. #Company Agilent Technologies Ge Healthcare Life Sciences do Brazil Johnson & Johnson Abbott Beckman Coulter Diagnostics Bayer Hamilton Thorne Biosciences Integrated DNA Technologies Microchip Biotechnologies, Inc. Myriad Genetics Commonwealth Biotechnologies, Inc. #Type Second Generation Third Generation #Application Treatment Research #CancerGenomeSequencing,#GenomicMedicine,#PrecisionOncology,#CancerResearch,#NextGenerationSequencing,#MedicalTechnology,#HealthcareInnovation,#Bioinformatics,#PersonalizedMedicine,#Oncogenomics

This week is Pulmonary Rehabilitation week where we recognize the role of pulmonary rehabilitation in enhancing the quality of life of individuals with chronic lung disease like COPD. GD3 is a fully integrated CRO, offering end-to-end solutions to further drug discovery and development programs to fulfill the unmet needs of chronic lung disease. GD3 offers: • Disease models including Model Of Murine Hypersensitivity Pneumonitis, Murine Model Of Pulmonary Fibrosis And Chronic Inflammation, Allergen-induced Pulmonary Inflammation for Asthma, and ovalbumin-induced pulmonary inflammation model, Model Of Murine Pulmonary Aspergillosis • Capabilities include: oncology and xenograft studies, oncology pharmacology models, oncology toxicology and pharmacokinetics, oncology histopathology, immunotherapy • Extensive experience with: small molecules, biologics, immunotherapy, gene therapy, stem cells, devices and implants, combination products, VX2 cell lines • Supporting capabilities: cystic fibrosis screening, gene expression profiling, fibrosis biomarkers, custom in vitro assay development. • Clinical Trial Management Click the following link to speak with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/ezTBzjzk

Will you be at #AACR2024 in San Diego? See Pieter Mestdagh poster (5182) on how to harness tumor RNA sequencing data to predict how well patients will respond to immune checkpoint inhibitor (ICI) cancer treatments. 💻 Pieter and the team have developed a computational method for measuring predictive biomarkers directly from a tumor's RNA sequencing data. Schedule a meeting with Pieter now 👉 https://bit.ly/3HQzLHL #CancerResearch #PrecisionMedicine #ImmunoOncology

Webinar Recap: Innovations in Cancer Organoid Modelling for Drug Discovery 🎓   Today, I attended an insightful webinar hosted by Labroots and sponsored by Thermo Fisher Scientific, focusing on the latest developments in cancer organoid (tumoroid) technology and its promising implications for drug screening. Here are some key takeaways: · Tumoroids as Powerful Models for Drug Discovery Workflows · Tumoroids offer a more functionally relevant target in functional compound screening assays. · They represent the diversity of donor genetic backgrounds. · Compatible with automation and multiplexed assay readouts. Key Speakers and Topics: 🔬 Dr. Colin Paul (Cell Biology R&D Staff Scientist, Thermo Fisher Scientific) >> Discussed the crucial role of tumoroids in drug discovery. >>Detailed a comprehensive 5-step tumoroid compound screening workflow using colorectal cancer (CRC) as an example. >>Provided future perspectives on tumoroid drug screening. 🔬 Dr. Thierry Jarde (Laboratory Head, Department of Anatomy and Developmental Biology, Monash University) >>Presented on modeling breast cancer using patient-derived tumor organoids. >>Covered current treatments for advanced breast cancer and personalized medicine approaches. >>Showcased the mini breast tumor model and the establishment of organoids from multiple subtypes. >>Discussed the multi-omics characterization of breast cancer organoids (including WES, histology, single-cell RNA sequencing, proteomics, and drug testing). >>Highlighted that breast cancer organoids are amenable to drug testing and can predict therapy responses. The session concluded with a robust Q/A segment, enriching the discussion with practical insights and expert opinions. This webinar highlighted how next-gen tumoroid models, platforms like OncoPro medium, and Single cell RNA sequencing analysis are shaping the future of cancer research and care, making strides toward precision medicine, improving the efficacy of treatments, and reducing drug candidate attrition rates. Thank you to Labroots, Thermo Fisher Scientific, and all the speakers for this enlightening session! #CancerResearch #DrugDiscovery #Organoids #PrecisionMedicine #BreastCancer #ThermoFisherScientific #Labroots #Webinar #bioinformatics #trnascriptomics #scrnaseq #ngs

This week is Pulmonary Rehabilitation week where we recognize the role of pulmonary rehabilitation in enhancing the quality of life of individuals with chronic lung disease like COPD. GD3 is a fully integrated CRO, offering end-to-end solutions to further drug discovery and development programs to fulfill the unmet needs of chronic lung disease. GD3 offers: • Disease models including Model Of Murine Hypersensitivity Pneumonitis, Murine Model Of Pulmonary Fibrosis And Chronic Inflammation, Allergen-induced Pulmonary Inflammation for Asthma, and ovalbumin-induced pulmonary inflammation model, Model Of Murine Pulmonary Aspergillosis • Capabilities include: oncology and xenograft studies, oncology pharmacology models, oncology toxicology and pharmacokinetics, oncology histopathology, immunotherapy • Extensive experience with: small molecules, biologics, immunotherapy, gene therapy, stem cells, devices and implants, combination products, VX2 cell lines • Supporting capabilities: cystic fibrosis screening, gene expression profiling, fibrosis biomarkers, custom in vitro assay development. • Clinical Trial Management Click the following link to speak with one of GD3's experts to learn more about how we can provide innovative support to advance the success of your program. https://lnkd.in/ezTBzjzk